Cefazolin Shows Promise in Reducing Kidney Injury in Bloodstream Infections

Recent trial results indicate that cefazolin may be a safer alternative to traditional treatments for bloodstream infections.

A
Aapla Nagpur Desk
17 Nov 2026, 4:48 PM IST · 2 min read
Source: Emjreviews
Cefazolin Shows Promise in Reducing Kidney Injury in Bloodstream Infections
KEY TAKEAWAYS
1

Cefazolin demonstrated noninferiority in 90-day mortality compared to traditional penicillins.

2

Acute kidney injury rates were significantly lower in patients treated with cefazolin.

3

The findings support cefazolin as a viable option for treating serious MSSA infections.

A recent international trial published in the New England Journal of Medicine has revealed that cefazolin may serve as a safer treatment option for bloodstream infections caused by methicillin-susceptible Staphylococcus aureus (MSSA). The study, part of the Staphylococcus aureus Network Adaptive Platform (SNAP) trial, assessed the efficacy and safety of cefazolin compared to flucloxacillin and cloxacillin in adult patients. The results indicate that cefazolin not only matches the mortality rates of traditional treatments but also significantly reduces the risk of acute kidney injury.

Conducted between February 2022 and August 2024, the open-label, randomized study involved 1,287 patients. The primary outcome measured was all-cause mortality within 90 days. Results showed that 15.0% of patients in the cefazolin group died within this period, compared to 17.0% in the penicillin group. The adjusted odds ratio for mortality was 0.81, indicating that cefazolin is not significantly less effective than its counterparts in preventing death.

In terms of kidney safety, cefazolin was associated with a notably lower incidence of acute kidney injury, occurring in 13.9% of patients treated with cefazolin versus 19.6% in those receiving flucloxacillin or cloxacillin. This difference of 5.7 percentage points, with an adjusted odds ratio of 0.67, suggests a strong probability that cefazolin is superior in minimizing kidney complications.

The implications of these findings are significant, as acute kidney injury can complicate the treatment of severe infections, necessitating more intensive monitoring and potentially altering treatment strategies. The favorable safety profile of cefazolin may be particularly beneficial for patients who are at higher risk for renal issues.

Despite the promising results, it is essential to consider that the trial was open-label, meaning both clinicians and patients were aware of the treatment being administered. Future research should further explore these findings in diverse populations. Overall, the study supports cefazolin as a noninferior alternative to traditional antistaphylococcal penicillins, with a favorable safety profile that could influence antibiotic treatment decisions for serious MSSA bloodstream infections.

💬What did you think of this story?What did you think?

Read Next

Cefazolin Reduces Kidney Injury in Bloodstream Infections